Xencor reports Q2 2026 results, sets ESMO date for XmAb819 kidney cancer data
Xencor confirmed a 2027 registration-enabling study plan for XmAb819 in kidney cancer, a 2H27 primary endpoint for XmAb942 in ulcerative colitis, and new Alexion settlement terms.
Xencor reported second quarter 2026 financial results on August 5, 2026, alongside a series of pipeline updates.
The company said it is on track to initiate a registration enabling study of XmAb819 as a monotherapy in advanced ccRCC during 2027.1 Phase 1 data in that setting were accepted for a proffered paper oral presentation at the ESMO Congress 2026, to be held October 23-27 in Madrid, Spain, with the presentation focusing on dose levels in intravenous expansion cohorts under evaluation as recommended Phase 3 doses.1 A sub-study for patients with intermediate- or poor-risk advanced ccRCC who have progressed after nivolumab in combination with ipilimumab as a first-line treatment is planned to open for enrollment in the third quarter of 2026.1
For the XmAb541/XmAb808 combination in Claudin-6-expressing tumors, Xencor disclosed monotherapy data showing an approximate 14% overall response rate in patients with ovarian cancer and an approximate 28% ORR in patients with germ cell tumors at the putative recommended Phase 3 dose.1 The FDA granted Fast Track designation to XmAb541 in July 2026 for patients with germ cell tumors who relapsed following two or more lines of platinum therapy or were refractory to prior platinum therapy.1
In ulcerative colitis, Xencor said enrollment expectations continue to support a XENITH-UC blinded interim analysis around year-end 2026 and reaching the primary endpoint of the 12-week induction period in 2H27.1 Separately, the company initiated a first-in-human study of its XmAb412 bispecific in the third quarter of 2026 and plans to present initial data in 1H27.1
On partnerships, Xencor said it will receive $105 million from Alexion under a settlement agreement resolving a dispute over U.S. royalties from Ultomiris sales,1 with the first $52.5 million payment expected in August 2026 and the second $52.5 million payment due within 14 days of the settlement's one-year anniversary.1 It also received a $10 million regulatory milestone payment in June 2026 tied to Zenas BioPharma's May 2026 BLA submission for obexelimab.1
On finances, Xencor expects to end 2026 with between $420 million and $440 million in cash, cash equivalents and marketable debt securities, with sufficient resources to fund operations through 2028.1 Cash stood at $486.4 million as of June 30, 2026, compared to $610.8 million as of December 31, 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.